Form 4: Teladoc Health Executive Acquires 43,800 Restricted Stock Units

Andrew Turitz, EVP of Corporate Development at Teladoc Health, reports the acquisition of 43,800 restricted stock units (RSUs) in a recent SEC filing.

Summary

• Andrew Turitz, the EVP of Corporate Development at Teladoc Health, filed a Form 4 with the SEC.
• The filing reports the acquisition of 43,800 restricted stock units (RSUs) on March 19, 2024.
• These RSUs represent a contingent right to receive one share of Teladoc Health common stock each.
• The RSUs vest over time, with one-third vesting on the first anniversary of the grant date and the remainder vesting in eight substantially equal quarterly installments starting June 1, 2025.
• Following the reported transaction, Turitz directly owns 43,800 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard executive compensation transaction. It's neither overwhelmingly positive nor negative.

Positives

• The acquisition of RSUs by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the RSUs suggests a long-term commitment by the executive to the company's success.

Industry Context

Executive compensation in the form of stock options and RSUs is a common practice in the healthcare technology industry to align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock-based compensation is a standard practice among publicly traded companies, especially in the tech and healthcare sectors.
• Companies like Amwell and Accolade also utilize RSUs as part of their executive compensation packages.
• The vesting schedules and amounts of RSUs can vary widely based on company size, performance, and individual executive roles.

Stakeholder Impact

• The acquisition of RSUs by an executive can have a minor positive impact on shareholder sentiment, reflecting confidence in the company's future.

Key Dates